Keyphrases
Disease-modifying Antirheumatic Drugs (DMARDs)
100%
Inflammatory Rheumatic Diseases
100%
Personalized Treatment
100%
Open Cohort Study
100%
New Biomarkers
100%
Biological Materials
50%
Blood Samples
50%
STrengthening the Reporting of OBservational Studies in Epidemiology
25%
Longitudinal Follow-up
25%
Tumor Marker
25%
Reporting Recommendations
25%
Adverse Events
25%
Routine Care
25%
Comorbid Factors
25%
Scientific Journals
25%
High Sensitivity
25%
Informed Consent
25%
Ethics
25%
Clinical Outcome Prediction
25%
Ethics Committees
25%
Predictive Biomarker
25%
Prognostic Study
25%
High Specificity
25%
Prognostic Biomarker
25%
Diagnostic Biomarker
25%
Treatment Failure
25%
Statistical Analysis
25%
Disease Pattern
25%
Protection Agency
25%
International Conference
25%
Clinical Data
25%
Treatment Efficacy
25%
Disease Course
25%
Drug Treatment
25%
Lifestyle Factors
25%
Data Protection
25%
Medicine and Dentistry
Biological Marker
100%
Rheumatic Disease
100%
Cohort Analysis
100%
Biocompatible Material
50%
Disease-Modifying Antirheumatic Drug
50%
Antirheumatic Agent
50%
Prognostication
25%
Informed Consent
25%
Blood Sampling
25%
Diseases
25%
Adverse Event
25%
Comorbidity
25%
Observational Study
25%
Disease Course
25%
Diagnostic Accuracy
25%
Tumor Marker
25%
Diagnosis
25%
Combination Therapy
25%
Cohort Effect
25%
Sensitivity and Specificity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatic Disease
100%
Biological Marker
100%
Cohort Study
100%
Antirheumatic Agent
50%
Biomaterial
50%
Disease Course
25%
Diseases
25%
Combination Therapy
25%
Adverse Event
25%
Tolerability
25%
Tumor Marker
25%
Observational Study
25%
Comorbidity
25%
Pharmacotherapy
25%